Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Sorafenib increases life expectancy in liver cancer patients

  • Comment
The drug sorafenib can increase the life expectancy of patients with advanced liver cancer by three months, a study has shown.

According to the study of 602 patients with advanced hepatocellular carcinoma, patients treated with the drug lived 44% longer than those who received a placebo.


Median overall survival was 10.7 months in a sorafenib group and 7.9 months in the placebo group.


‘This is the first time that we've had an effective systemic treatment for liver cancer,’ said lead author Josep Llovet, director of research in liver cancer at Mount Sinai School of Medicine in New York.

‘Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful.’

New England Journal of Medicine (2008) 359: 378-390

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.